Extended oral antibiotics are one of the effective approach to prevent or control prosthetic joint infections, but the timing of delivery to optimize patient outcomes are debated. The other name for prosthetic joint infection (PJI) is peri-prosthetic infection, an infection involving the adjacent tissues and joint prosthesis. Prosthetic joint infection is one of the common etiologies and complications of implant failure after joint replacement surgeries and is putting a financial burden on the global healthcare system, and significant psychological and physical morbidity on patients. The majority of prosthetic joint infection (PJI) occurs within one year of surgery and are initiated through the introduction of microorganisms during the surgery, caused through either direct contact or aerosolized contamination of the periprosthetic tissue or prosthesis.
Request for Brochure here : https://www.factmr.com/connectus/sample?flag=B&rep_id=5630
What are the factors boosting the Growth of the Extended Oral Antibiotics Market?
Extended oral antibiotics is likely to foster significant demand in the market due to the rising number of total joint arthroplasties (hip (THA) and knee (TKA) arthroplasty) and cases of prosthetic joint infections. Furthermore, the rising advancements in R&D for preventing or controlling prosthetic joint infections and introduction of immunoparticles, nanoparticles, novel antibiotics, photodynamic therapy, antimicrobial peptides, and lytic bacteriophages are some of the factors driving the growth of the global extended antibiotics market. Furthermore, the increasing geriatric population and antibiotics resistance is leading to the development of new antibiotics, which adds another factor driving the extended oral antibiotics market growth.
The approaching reimbursement scenario is expected to have a positive impact on the extended oral antibiotics market growth. The government is the primary payer for the majority of total joint arthroplasties, through Medicare spending. Furthermore, in addition to improving patient care, preventing prosthetic joint infections may save costs to the Medicare plans. Several strategies and reimbursements are on the horizon that will impact provider compensation for hospitals and physicians.
What are the Key Challenges that may restrain the Growth of the Extended Oral Antibiotics Market?
However, there are some factors that can hinder the growth of global extended oral antibiotics market growth such as lack of trained pathologist in performing the histological analysis, especially in poor countries and awareness of the disease diagnosis treatment. Furthermore, the stringent regulations and lack of FDA approvals in some regions may impact the global extended oral antibiotics market growth.
Request Customized Report as Per Your Requirements : https://www.factmr.com/connectus/sample?flag=B&rep_id=5630
Key players such as
- Arrevus, Melinta Therapeutics Inc.
- Nabriva Therapeutics plc
- Peptilogics Inc.
- elephus Medical LLC
others are actively involved in offering extended oral antibiotics.
How Increasing R&D to Augment Extended Oral Antibiotics Market Growth?
The rising demand for preventing or controlling prosthetic joint infection is encouraging key manufacturers to invest more in research activities to develop more extended oral antibiotics. Manufacturers are engaged in clinical trials for drug compounds to develop extended oral antibiotics. Few of them have got the FDA approval from the regulatory bodies.
- For example, Lefamulin (IV/Oral) compound of Nabriva Therapeutics plc, is in Phase I of clinical trial for the indications including prosthetic joint infection and osteomyelitis.
Moreover other players including Telephus Medical LLC and Melinta Therapeutics, Inc. have their compounds under pipeline for the treatment. This is one of the prime factor driving the growth of the global extended oral antibiotics market.
Key Segments of Extended Oral Antibiotics Market Covered in the Report
Based on drug type, the global extended oral antibiotics market has been segmented as
Based on distribution channel, the global extended oral antibiotics market has been segmented as
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Based on region, the global extended oral antibiotics market has been segmented as
- North America
- Latin America
- South Asia
- East Asia
- Middle East & Africa
Read More Trending and Similar Reports from Fact.MR : http://www.globenewswire.com/en/news-release/2019/05/14/1823788/0/en/Smartphone-based-Pregnancy-Point-of-Care-Testing-Emerging-as-a-Potential-Alternative-to-Lab-based-Diagnostics-Fact-MR.html
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website: https://www.factmr.com